Drugs / Irinotecan liposome injection
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06259058 | Apr 2024 → Apr 2026 overdue | malignant pancreatic neoplasm | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Irinotecan liposome injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06259058 ↗ |